Clinical Trial

Fructose Intestinal Gluconeogenesis

Study acronym: FIG
Recruiting
View on ClinicalTrials.gov →
Summary
This study will test the hypothesis that within a defined range of fructose intake, the ability to convert fructose to glucose (via gluconeogenesis) in the small intestine plays a protective role for the liver, shielding it from the deleterious effects of fructose. We will investigate whether this protective effect of the intestine is impaired in individuals with obesity.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-09-30.
Status change: Not Yet Recruiting → Recruiting 2026-03-04
Trial Details
NCT Number NCT07209202
Lead Sponsor Touro University, California
Collaborators: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Conditions Healthy Participants, Obese But Otherwise Healthy Participants
Enrollment 40 participants
Start Date 2026-03-02
Primary Completion 2030-06 (estimated)
Study Completion 2030-06 (estimated)
Updated on ClinicalTrials.gov 2026-03-06